Send to

Choose Destination
Vaccine. 2011 Feb 11;29(8):1538-44. doi: 10.1016/j.vaccine.2010.11.091. Epub 2010 Dec 14.

Non-toxic derivatives of LT as potent adjuvants.

Author information

Molecular Vaccinology Laboratory, Queensland Institute of Medical Research, Brisbane, QLD 4006, Australia.


The heat-labile enterotoxin of Escherichia coli (LT) consists of an enzymatically active A subunit (LTA) and a pentameric B subunit (LTB). LT has been extensively studied as a potent modulator of immune responses but wild-type LT is toxic and therefore unsuitable for clinical use. Approaches pursued to avoid the toxicity associated with the use of the native toxin while retaining its adjuvant properties have included isolation of subunit B (LTB) and construction of non-toxic LT AB complex mutants, such as LTK63 mutant. Here we review the immunomodulatory characteristics of LTB and LTK63 and their potential as mucosal and parenteral vaccine adjuvants.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center